Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials

The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence (rCDI) in adults at high risk for rCDI. Efficacy o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Clin Microbiol Infect Dis
Main Authors: Bouza, Emilio, Cornely, Oliver A., Ramos-Martinez, Antonio, Plesniak, Robert, Ellison, Misoo C., Hanson, Mary E., Dorr, Mary Beth
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497347/
https://ncbi.nlm.nih.gov/pubmed/32504314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10096-020-03935-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados